<DOC>
	<DOCNO>NCT00202618</DOCNO>
	<brief_summary>The purpose trial evaluate reduction urinary albumin excretion angiotensin receptor blocker ( ARB ) , valsartan , comparison calcium channel blocker ( CCB ) , amlodipine , Japanese hypertensive patient type 2 diabetes mellitus microalbuminuria strict blood pressure control , compare additional effect ARB CCB combination angiotensin-converting enzyme ( ACE ) inhibitor treatment .</brief_summary>
	<brief_title>Rationale Design Shiga Microalbuminuria Reduction Trial</brief_title>
	<detailed_description>Microalbuminuria diabetic patient establish risk marker progression diabetic nephropathy cardiovascular mortality . Intervention trial demonstrate drug blockade renin-angiotensin system reduce microalbuminuria Caucasian patient type 2 diabetes mellitus microalbuminuria , regardless blood pressure level . However , remain uncertain whether angiotensin receptor blocker calcium channel blocker give great reduction microalbuminuria . The Shiga Microalbuminuria Reduction Trial ( SMART ) prospective , multicentre , randomize , active-controlled , two-arm parallel treatment group comparison study aim evaluate reduction microalbuminuria 160 Japanese hypertensive patient type 2 diabetes mellitus microalbuminuria . The trial consist 8-week observation period screen washout , 24-week intervention period . After observation period , patient randomize either amlodipine 5 mg daily valsartan 80 mg daily initial dose . After four week , patient achieve target blood pressure ( &lt; 130/80 mmHg ) initial dose study drug , dose titrated amlodipine 10 mg daily valsartan 160 mg daily . The primary endpoint change rate urinary albumin excretion baseline , normalization microalbuminuria , 50 % reduction urinary albumin excretion baseline , compare treatment group . This study provide additional data treatment hypertension microalbuminuria important health care implication Japanese patient type 2 diabetes .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Hypertensive patient type 2 diabetes Microalbuminuria define urinary albumin excretion 30 300 mg/gCr Type 1 diabetes mellitus Pregnant woman woman childbearing potential Severe hypertension ( &gt; 180/110 mmHg ) , malignant hypertension , secondary hypertension History cardiovascular disease precede 6 month ( include symptomatic heart failure , unstable angina , myocardial infarction , performance percutaneous transluminal coronary angioplasty [ PTCA ] , coronary artery bypass graft [ CABG ] , severe arrhythmia , second third degree atrioventricular [ AV ] block ) History clinically significant valvular disease ( e.g. , aortic stenosis , mitral insufficiency ) History cerebral infarction , cerebral hemorrhage , transient ischemic attack Serum creatinine level &gt; 1.5 mg/dl Persistent hematuria Serum potassium &gt; 5.6 mEq/L ( hyperkalemia ) Severe hepatic disorder ( e.g. , hepatic failure , hepatic cirrhosis ) Complication allergy potential clinical concern Hypersensitivity ARBs CCBs Gastrointestinal surgery gastrointestinal disorder could interfere drug absorption Autoimmune disease Participation intervention trial within 3 month prior observation period Patients unwilling unable comply trial protocol Concomitant use ARBs , CCBs , potassiumretaining diuretic</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Microalbuminuria</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Calcium channel blocker</keyword>
	<keyword>Valsartan</keyword>
	<keyword>Angiotensin type 2 receptor blocker</keyword>
</DOC>